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Abstract
Background: Since the novel H7N9 avian influenza outbreak occurred in China in 2013, neuraminidase inhibitors
(NAIs) such as oseltamivir and peramivir have been used as first-line drugs to treat the influenza virus infection. This
study aimed to compare the efficacy of oseltamivir-peramivir combination therapy versus oseltamivir monotherapy.
Methods: A retrospective study of 82 H7N9 confirmed patients was conducted by reviewing medical charts at the
First Affiliated Hospital of ZheJiang University in China from April 1, 2013 to Feb 28, 2014. The patients’ clinical
information was collected systematically, and we compared the virology and clinical data between oseltamivir
monotherapy group (43 patients) and oseltamivir-peramivir combination group (39 patients).
Results: The median duration from NAIs administration to H7N9 virus-negative in oseltamivir monotherapy group
and oseltamivir-peramivir combination group was 6.50 and 7.00 days (p >0.05), respectively. The median decline of
Day 2 to Day 0 (initiation of NAIs therapy) viral load was 0.00 and 0.69 log10 copies/μl (p >0.05) respectively in the
monotherapy vs. combination therapy groups. The incidence of new Acute Respiratory Distress Syndrome during
NAI administration was 63.89 and 77.78 % (p >0.05); while the mortality rates were 25.58 and 43.59 % (p >0.05) in
the oseltamivir group vs. oseltamivir-peramivir group.
Conclusions: Our results suggest that in adults with H7N9 virus infection, the use of oseltamivir-peramivir
combination therapy was not superior to oseltamivir monotherapy.
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Background
Since the novel H7N9 avian influenza outbreak occurred
in China in 2013, neuraminidase inhibitors (NAIs) such
as oseltamivir and peramivir have been important and
efficacious in curbing the viral infection [1]. From previ-
ous experience with influenza infections, the wide use of
a single antiviral drug likely leads to drug resistance
which can reduce the effectiveness of antiviral activity
[2–6]. Furthermore, oseltamivir-resistant viral strains
have been identified [7]. In order to decrease the emer-
gence of other drug-resistant virus in the future, while at
the same time ensure efficacious antiviral effects, new
treatment strategies are required.
One such strategy was the combination of two NAIs
to treat influenza infections. The basis of the combin-
ation therapy was that two or triple antiviral drugs may
have additive synergistic effects and reduce drug resist-
ance at the same time [2–6]. Combination of oseltamivir
and peramivir showed additive to synergistic activity
against Influenza A (H1N1) virus in vitro and in mice
[8]. Another study showed possible additive to antagon-
istic effects in vitro [9]. In addition, a study carried out
in mice showed the combination of oseltamivir and
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zanamivir therapy was not superior to zanamivir mono-
therapy [10]. Furthermore, a randomized double-blind
and placebo-controlled clinical trial in adults with sea-
sonal Influenza A H3N2 virus infection during 2008–2009
showed the oseltamivir-zanamivir combination therapy
was not more effective than either oseltamivir or zanami-
vir monotherapy [11]. However, since the H7N9 virus has
a different structure compared to H3N2, the effect of
combination treatment versus monotherapy is unknown.
Herein, we carried out a retrospective study to evaluate
the efficacy of antiviral therapy of oseltamivir-peramivir
combination compared to oseltamivir monotherapy in the
treatment of adult patients with H7N9 virus infection.
Methods
Ethics statement
This study was approved by the First Affiliated Hospital
of ZheJiang University ethics board.
Patient enrollment
During the outbreak, patients with influenza symptoms
onset (temperature ≥38.0 °C or at least one of respira-
tory symptoms including rhinorrhea, sore throat, cough,
or nasal congestion), pneumonia of unknown origin, or
patients who had recently been in close contact with
birds or a H7N9-confirmed patient were screened in this
study. Respiratory specimens (nasopharyngeal, oropharyn-
geal swabs or sputum) and blood samples were collected
for H7N9 virus laboratory tests and conducted in these sus-
pected cases. There were three methods for H7N9 labora-
tory diagnosis: real-time reverse-transcriptase-polymerase-
chain-reaction assay (RT-PCR) assay, viral isolation, and
H7N9 serological testing by modified hemagglutinin
inhibition assay [12, 13]. The patients with laboratory
diagnosis were defined as confirmed H7N9 patients
[13]. Regardless of clinical severity, the confirmed
H7N9 patients were admitted into the hospital and
treated with NAIs.
This retrospective study was performed at the First
Affiliated Hospital of ZheJiang University. Enrollment
criteria included age ≥18 years with confirmed Influenza
A (H7N9) virus infection, and acceptance of oral oselta-
mivir monotherapy or oral oseltamivir and intravenous
peramivir combination therapy. All the 82 cases enrolled
in the study were admitted during the study period from
April 1, 2013 to Feb 28, 2014.
Data collection
We reviewed medical charts and used standardized
forms to gather information retrospectively. Clinical
and laboratory information was collected systema-
tically from admission to discharge for every patient,
including demographic information, baseline and follow-
up clinical information.
After admission, respiratory specimens (nasopharyngeal
swabs, sputum, or endotracheal aspirates) were collected
daily to determine H7N9 viral RNA by PCR analysis. The
second negative result of two respiratory samples collected
in two-consecutive days was considered the time to stop
NAIs therapy and represented an undetectable viral RNA
level. We defined the duration between NAI administra-
tion and undetectable viral RNA level as the time from
NAI administration to virus-negative. As we could not
determine the exact virus infection time, following an-
other report [14], we defined the interval between symp-
tom onset and the date of the first negative result of two
consecutive respiratory samples as the RNA shedding.
Severity of illness was evaluated according to the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score on the day of admission. Moderate-to-severe Acute
Respiratory Distress Syndrome (ARDS) as diagnosed by
the ARDS Berlin definition, i.e. severe hypoxemia (PaO2/
FiO2 ≤200 mmHg with PEEP ≥5 cm H2O), associated with
bilateral opacities on chest X-ray, which could not be fully
explained by cardiac failure or fluid overload.
Outcome measures
The primary outcome was the time from NAI adminis-
tration to virus-negative. The second outcome was the
decline of virus load (measured by log10 virus load)
between Day 0 (the day NAI therapy was initiated) and
Day 2 in patients with confirmed H7N9 virus infection.
Based on the viral shedding kinetics in seasonal influ-
enza patients treated by NAIs, the Day 2 viral out-
come seemed the most suitable to evaluate virology
effects [15, 16]. The clinical end points included the
incidence of ARDS after NAIs administration and in-
hospital mortality.
Statistical analysis
Categorical variables were calculated by frequency ana-
lysis. The numerical variables of normal distributions was
represented by means (±standard deviations), abnormal
distributions was represented by medians (interquartile,
IQR). Two sample Student’s t test was performed to assess
the significance of the time from NAI administration to
H7N9 virus-negative, the decline of log10 virus load
between Day 0 and Day 2. Chi-square test was performed
to compare the rate of new ARDS after NAI administra-
tion and the total in-hospital mortality. All analyses were
two-tailed and the P value <0.05 was considered sig-




From April 1, 2013 to Feb 28, 2014, about 1950 patients
were tested for H7N9 viral infection, and 87 patients
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were positive. Five of them received other antiviral drugs
other than oseltamivir or peramivir. Therefore, a total of
82 adult patients were enrolled in our study. The mean
age was 58.21 years (±14.31) and 68.29 % (56 patients)
were male. Forty four (53.66 %) patients had one or
more coexisting conditions. Hypertension, diabetes,
coronary heart disease were the most common coexist-
ing conditions (Table 1). The most common symptom
was fever (82 patients, 100 %), followed by cough (73
patients, 89.02 %), Sputum production (52 patients,
63.41 %), and shortness of breath (52 patients, 63.41 %)
(Table 1).
All the patients received NAIs therapy after admis-
sion. The median time from symptom onset to NAIs
therapy was 6.00 days (interquartile range, 4 to 8). Eight
patients (9.76 %) received NAIs therapy within 48 h
after the symptom onset, and 35 patients (42.68 %)
within 5 days, 47 patients (57.31 %) more than 5 days.
Forty two patients (51.22 %) received glucocorticoid
therapy, including intravenous methylprednisolone and
intravenous dexamethasone. There were 41 (50 %) pa-
tients developed bacterial or fungal infection or colonisa-
tion by positive sputum culture during hospitalization,
including Acinetobacter baumannii, Klebsiella pneumo-
niae, Staphylococcus aureus, Burkholderia cepacia and
Candida albicans.
Among the 82 patients, 39 patients (47.56 %) were
enrolled in the first H7N9 wave from April 1, 2013 to
May 31, 2013, and 43 patients (52.43 %) were enrolled in
the second wave from Nov 30, 2013 to Feb 28, 2014. In
the first H7N9 wave, the median age was 63 years(IQR,
55 to 70) and 46.15 % (18 patients) were ≥65 years, while
in the second wave, the median age was 57 years(IQR,
47 to 64) and 51.16 %(22 patients,) were 50–64 years.
Compared with the first wave, more patients in the
second wave had no coexisting condition (Table 1). The
rates of ARDS were respectively 27/39 (69.23 %) and 33/
43 (76.74 %), in-hospital mortality were respectively 9/39
Table 1 Demographic and clinical characteristics of 82 confirmed H7N9 patients
Characteristic No. of cases (%) P value*
Total (n = 82) The first wave (n = 39) The second wave (n = 43)
Male patients 56 (68.29)
Age (years)
18–49 19(23.17) 8(20.51) 11(25.58) 0.09
50–64 35(42.68) 13(33.33) 22(51.16)
≥65 28(34.15) 18(46.15) 10(23.26)
Coexisting condition
Any 44(53.66) 23(84.62) 21(48.84) 0.38
Hypertension 38(46.34)
Diabetes 17(20.73)
Coronary heart disease 6(7.31)
Cerebrovascular disease 4(4.86)
Chronic obstructive pulmonary disease 3(3.65)
Cancersa 2(2.43)
Immunosuppressionb 2(2.43)










aCancers included leukemia and lymphoma
bImmunosuppression caused by the immunosuppressive drug after renal transplantation
cGastrointestinal symptom included nausea, vomiting, diarrhea, and abdominal pain
*The p value was calculated between the first and second H7N9 wave
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(23.08 %) and 19/43 (44.19 %) in the first and second
wave of H7N9.
Based on the different NAIs drugs they accepted, the 82
patients were divided into oseltamivir monotherapy ther-
apy group (O, n = 43, with 39 cases enrolled in the H7N9
first wave, four cases in the second wave) and oseltamivir-
peramivir combination therapy group (OP, n = 39, all
enrolled in the second H7N9 wave).
In the oseltamivir monotherapy group, 23 patients
(53.49 %) were treated with oseltamivir dosage of 75 mg
orally twice daily, 19 patients (44.19 %) were treated with
150 mg twice daily, and one patient (2.33 %) received
75 mg once. In the oseltamivir-peramivir combination
therapy group, 24 patients (61.54 %) were treated with
75 mg oseltamivir twice and 600 mg peramivir once
daily; five patients (12.82 %) were treated with 75 mg
oseltamivir twice and 300 m g peramivir once daily; six
patients (15.38 %) were treated with 150 mg oseltamivir
twice and 600 mg peramivir once daily; two patients
(5.13 %) were treated with 150 mg oseltamivir twice and
300 mg peramivir once daily; one patient (2.56 %) chan-
ged oseltamivir dosage to 150 mg twice daily after
10 days of 75 mg twice daily with 600 mg peramivir
once daily; one patient (2.56 %) changed oseltamivir dos-
age to 75 mg twice daily after 6 days of 75 mg once daily
in the local hospital with 600 mg peramivir once daily.
Endpoints
Primary outcome: duration from NAIs therapy to H7N9
virus negative
Among the 82 patients, there were seven patients whose
H7N9 virus status was positive till death in the oseltamivir-
peramivir group, and five in oseltamivir monotherapy
group. Excluding these 12 patients, the oseltamivir mo-
notherapy group had 38 (88.37 %) patients and the
oseltamivir-peramivir group had 32 (82.05 %) patients. The
median time from NAIs therapy to negative viral RNA
shedding of the remaining 70 patients was 7.00 days (IQR,
5 to 9). The median duration of viral shedding in the whole
82 patients was 12.00 days (IQR, 9.75 to 17), in the oselta-
mivir monotherapy group was 11 days (IQR, 9 to 16.25),
and in the oseltamivir-peramivir combination group was
13 days (IQR, 11 to 17). Baseline information of the two
groups is listed in Table 2. There was no difference between
the two groups in regard to age, gender, the time from
symptom onset to antivirus treatment, the viral load before
NAIs treatment and the APACHE II score before NAIs
therapy (p >0.05). The median time from antiviral treat-
ment to viral-negative in oseltamivir monotherapy group
was 6.50 days (IQR, 4 to 8), and oseltamivir-peramivir
combination therapy group was 7.00 days (IQR, 6 to 9.75)
(p >0.05; Table 2). A total of seven patients in the oseltami-
vir monotherapy group and 11 patients in the oseltamivir-
peramivir combination therapy group died after their
H7N9 status was viral-negative.
Secondary outcome: decline of log10 virus load between
Day 0 and Day 2
Among the 82 confirmed patients, there were 60 pa-
tients with both Day 0 and Day 2 viral data, comprising
31 patients in the oseltamivir-peramivir combination
therapy group, and 29 patients in oseltamivir monother-
apy group. The median viral load decrease of Day 2 to
Day 0 was 0.69 log10 copies/μl (IQR,0.31 to 1.56) in the
oseltamivir-peramivir combination therapy group, and
0.00 log10 copies/μl (IQR, −0.59 to 1.18) in the oseltami-
vir monotherapy group (p >0.05; Table 3).
Clinical outcome: the incidence of new Acute Respiratory
Distress Syndrome after NAIs administration and in-hospital
mortality
Of the total 82 patients, 7 (18.42 %) patients had ARDS
before receiving NAIs treatment in the oseltamivir
monotherapy group, and 3 (9.10 %) patients in the
oseltamivir-peramivir combination therapy group. These
10 patients were therefore excluded from this portion of
the study, and 36 patients remained in each treatment
group. The incidence of newly-developed ARDS during
Table 2 Baseline information and the duration from NAIs therapy to H7N9 virus-negative
Patients Characteristics O + P O P Value
All patients n = 39 n = 43
Patients whose virus still positive till death n = 7 n = 5
Study patients n = 32 n = 38
Age (years): mean (SD) 55.22(14.25) 60.21(14.89) 0.64
No. of male (%) 22(68.75 %) 27(71.05 %) 1.00
Time from symptom onset to NAIs administration (days):median (IQR) 7.00(4.25, 8.75) 5.00(4.00, 7.00) 0.52
APACHE II score: mean(SD) 17.47(8.08) 20.82(8.17) 0.87
Viral load(log10 /ul) at day 0: median(IQR) 3.30(2.91, 4.1) 3.29(2.70, 4.47) 0.12
Duration from NAIs taken to H7N9 virus negative(days): median(IQR) 7.00(6.00, 9.75) 6.50(4.00, 8.00) 0.67
O oseltamivir monotherapy, O+P oseltamivir-peramivir combination therapy, IQR interquartile range, percentile 25 – percentile75
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NAI therapy was 23/36 (63.89 %) in oseltamivir mono-
therapy group and 28/36 (77.78 %) in the oseltamivir-
peramivir combination therapy group (p >0.05; Table 4).
In the 82 patients, the overall in-hospital mortality was
43.59 % in oseltamivir-peramivir combination therapy
group, and 25.58 % in oseltamivir monotherapy group
(Table 5).
Discussion
Our retrospective study examined the effect of oseltamivir-
peramivir combination antiviral therapy in H7N9 influenza,
as compared to oseltamivir monotherapy. The results
showed that the oseltamivir-peramivir combination therapy
not apparently superior to oseltamivir monotherapy in the
adults with H7N9 virus infection during April 1, 2013 to
Feb 28, 2014 in China. To the best of our knowledge, ours
is the first study to compare the efficacy of oseltamivir-
peramivir combination therapy and oseltamivir monother-
apy on the H7N9 virus.
Most in vitro studies that assess the efficacy of com-
bination NAIs therapy have shown synergism and ad-
ditive effects. The combination of antivirals not only
decreases the emergence of resistant strains, but also
ensures antiviral effect [2–6]. Therefore, the combin-
ation of oseltamivir and peramivir was hypothesized to
be more effective. However, our investigation showed
that oseltamivir-peramivir combination was not superior
to oseltamivir monotherapy. In other words, the combin-
ation did not lead to additive effects at least. Our findings
are in agreement with a clinical trial that showed a lack of
additive or synergistic effect between oseltamivir and
zanamivir for seasonal Influenza A H3N2 virus during the
2008–2009 season [11], and a randomized trial that found
no difference between oseltamivir-zanamivir combination
and oseltamivir alone for Influenza A (H1N1)pdm09 virus
[17]. Oseltamivir and peramivir are both neuraminidase
inhibitors with similar mechanisms of action. Synergy or
additive effects generally occur in antiviral drugs with
different mechanisms of action [8]. Malaisre et al. reported
that compared oseltamivir, peramivir acts on neuraminid-
ase N1, and found that peramivir had a tighter binding to
neuraminidase N1 than oseltamivir [18], and antagonistic
interactions may exist. Therefore, further research is
needed to investigate whether peramivir has a tighter
binding to neuraminidase N9 which could prevent the
action of oseltamivir.
The patients initiated NAI therapy a relatively long time
after the onset of influenza symptoms (median 6.00 days,
IQR, 4 to 8). Wiku Adisasmito et al. found that H5N1
patients could still benefit when initiated oseltamivir up to
6–8 days after onset of symptoms [19]. Here, the patients
who initiated NAI treatment more than 5 days after onset
of symptoms remained enrolled in the current study.
However, the timing of NAI initiation was important.
Table 3 Baseline information and the decrease of log10 virus load between Day 0 and Day 2
Patients Characteristics O+P group O group P value
All patients n = 39 n = 43
Patients with both day 0 and day 2 available specimens n = 31 n = 29
Age (years): mean (SD) 55.45(14.80) 60.79(14.62) 0.94
No. of male (%) 22(56.41) 22(51.16) 0.45
Time from symptom onset to NAIs administration (days):median(IQR) 7.00(5.00, 8.00) 5.00(4.00, 7.00) 0.46
APACHE II score: mean(SD) 18.53(8.83) 22.69(8.53) 0.83
Viral load decrease between day 2 and day 0 (log10 /ul): median(IQR) 0.69(0.31, 1.56) 0.00(−0.59, 1.18) 0.06
O oseltamivir monotherapy, O+P oseltamivir-peramivir combination therapy, IQR interquartile range, percentile 25 – percentile75
Table 4 Baseline and the incidence of ARDS
Patients Characteristics O+P group O group P value
All patients n = 39 n = 43
patients had already got ARDS before received NAIs n = 3 n = 7
Study patients n = 36 n = 36
Age (years): mean (SD) 52.58(12.70) 59.31(13.85) 0.44
No. of male (%) 24 24 1.00
Time from symptom onset to NAIs administration (days):median(IQR) 7.00(4.25, 8.00) 6.00(4.00,8.00) 0.57
Viral load(log10 /ul) at day 0: median(IQR) 4.07(3.00, 4.47) 3.58(2.89,4.47) 0.73
APACHE II score: mean(SD) 19.17(8.28) 20.22(7.76) 0.58
New ARDS developed patients (%) 28(77.78) 23(63.89) 0.30
O oseltamivir monotherapy, O+P oseltamivir-peramivir combination therapy, IQR interquartile range, percentile 25 – percentile75
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Early treatment was related to better outcome. Jain et al.
showed the administration of antiviral drugs within two
days of the onset of symptoms was the only independent
risk factor affecting the prognosis of H1N1 [20]. The
Centers for Disease Control and Prevention of the United
States (CDC) recommends the initiation of antiviral drugs
within 5 days of onset of symptoms for H1N1 infections.
Regarding H7N9 virus, delayed antiviral therapy may be
associated with more severe illness [21]. Gao HN et al.
pointed out that the risk of death increased when antiviral
therapy was initiated in more than 5 days after onset of
symptoms [22]. In the current study, as many as 47.56 %
patients (39) initiated NAIs in more than 5 days after
onset of symptoms. The delayed administration of NAIs
might affect the therapeutic effect of NAIs. There might
be a difference between oseltamivir-peramivir combin-
ation therapy and oseltamivir monotherapy when admin-
istered within 48 h or 5 days after symptom onset. Smee
et al. reported that oseltamivir-peramivir combination
performed better than either monotherapy in vitro and in
mice infected with Influenza A/NWS/33 (H1N1) virus [8].
In that study, the drugs were administered immediately
after viral infection.
In the current study, most patients in the oseltamivir
monotherapy group (39 patients, 90.70 %) were enrolled
in the first H7N9 wave, while all the patients in the
oseltamivir-peramivir combination group were enrolled
in the second H7N9 wave. It was observed that H7N9
virus in the second wave to infect younger patients with
less concomitant disease. The second wave had higher
mortality. The influenza virus is an RNA virus, with a high
error rate during transcription [23]. The oseltamivir-
resistance is more likely to emerge in severe cases [24],
such as H7N9 cases. During the first H7N9 wave in China,
oseltamivir-resistant H7N9 virus had already emerged.
NA-E119V, NA-I222K, and NA-I222R reduced inhibition
by oseltamivir, and NA-R292K caused highly reduced in-
hibition by oseltamivir and peramivir [7]. The NA-R292K
mutation has been reported to emerge within 2 days of
administration of oseltamivir, and it is associated with the
poor clinical outcome [1]. Corticosteroid therapy seems to
be a risk factor [1]. The widespread use of oseltamivir and
corticosteroid by the current patients may have caused a
mutation to emerge. However, the H7N9 viral RNA was
not sequenced for these 82 cases, so it was not possible to
know whether there were any mutations associated with
resistance to NAIs and the difference in H7N9 viral
sequence between two groups. Further research is needed.
In the current study, the dosage of NAI varied widely.
The majority of the patients (38 patients, 94.44 % in the
oseltamivir monotherapy group; 42 patients, 97.67 % in
the oseltamivir-peramivir combination group) received
the standard or double dosing of NAIs. Two oseltamivir
dose-comparison studies in influenza showed no differ-
ence from standard dosage (75 mg twice daily) or double
dosage (150 mg twice daily) in virological clearance or
clinical outcome [25, 26]. One hypothesis is that the
action of oseltamivir may be saturable [26]. Previous
studies indicate that doubling oseltamivir dosage had no
effect on viral clearance or clinical outcome. However,
for oseltamivir-peramivir combination therapy, the pro-
portion of the two drugs may influence the result. Nguyen
et al. compared the combinations of zanamivir and pera-
mivir or oseltamivir in vitro and found a concentration-
related additive to antagonistic effects for H1N1 viruses
[9]. The combination of different concentrations of
oseltamivir and peramivir for Influenza A (H1N1) virus
in vitro and in mice showed additive to synergistic
effects [8]. In this way, the various combination ratios
may affect the result. Suitable concentration ratios may
be necessary to produce additive or synergistic effects
when treating H7N9 patients with combinations of
oseltamivir and peramivir.
The current study suggested that the median duration
of viral shedding of H7N9 virus was 12 days (IQR, 9.75
to 17). The viral load of the seasonal influenza usually
shed for 5 days in adults [27, 28]. The 2009 H1N1 shed
for a median of 5 days (3 to 6) [14]. The current results
showed that H7N9 could be shed for a longer period of
time than 2009 H1N1 and seasonal influenza. A study
showed that a longer viral shedding interval to be related
to severe illness in H7N9 patients [21]. Similar findings
were observed in influenza A(H1N1) patients [1]. In
influenza H1N1, the early treatment within 2 days of
Table 5 Baseline information and in-hospital mortality
Patients Characteristics O+P group O group P value
all patients included in the study n = 82 n = 39 n = 43
Age (years): mean (SD) 56.51(13.86) 59.74(14.71) 0.53
No. of male (%) 27(69.23 %) 29(67.44 %) 1.0
Time from symptom onset to NAIs administration (days):median(IQR) 7.00(5.00,8.00) 5.00(4.00,7.00) 0.16
APACHE II score: mean(SD) 19.05(8.41) 21.09(8.33) 0.86
Viral load(log10 /ul) at day 0: median(IQR) 3.34(3.06, 4.45) 3.53(2.84, 5.07) 0.08
Mortality(%) 17(43.59) 11(25.58) 0.11
O oseltamivir monotherapy, O+P oseltamivir-peramivir combination therapy, IQR interquartile range, percentile 25 – percentile75
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onset of symptoms could reduce the duration viral RNA
shedding [14]. Studies have reported that delayed treat-
ment with oseltamivir may be related to delayed viral
clearance [26]. Prolonged positive viral RNA had been
shown to correlate with morbidity in hospital [26]. In
the current study, the delayed administration of NAIs
might contribute to the high morbidity. Therefore, the
early initiation of NAIs is recommended.
There are several limitations to the current study.
First, it was a retrospective study and the sample size
was too small for robust investigation in subgroups of
patients. Despite the use of a standardized case-report
form, not all information was available for all 82 pa-
tients. Secondly, the H7N9 viral RNA of these 82 cases
was not sequenced for analysis of antiviral resistance. It
was not possible to determine whether there were any
mutations associated with resistance to NAIs in either
group, especially the NA-R292K. Third, the dosage of
oseltamivir and peramivir varied widely. The heterogen-
eity may influence the antiviral effect of two groups.
Fourthly, most people in our study received NAIs more
than 5 days, not the optimal time. It may influence the
effect of the NAIs. Further prospective clinical studies
should be performed to compare the effect between
NAI monotherapy and combination therapy with two
NAIs with standardization NAI administration. And
the NAI-resistance should be analyzed.
Conclusions
In conclusion, our study has shown that oseltamivir-
peramivir combination was not superior to oseltamivir
monotherapy for treating H7N9 influenza; therefore the
use of the combination therapy may not be useful when
treating critically ill patients.
Abbreviations
APACHE: acute physiology and chronic health evaluation; ARDS: acute
respiratory distress syndrome; CDC: Centers for Disease Control and
Prevention of American; IQR: interquartile range; NAIs: neuraminidase
inhibitors; O: oseltamivir; P: peramivir; RT-PCR: real-time reverse-transcriptase-
polymerase-chain-reaction assay.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
Conceived and designed the experiments: HG, WL, YY, LT, LL. Data collection:
YZ, PC, LY; Laboratory examination: SZ, HO, XW. Analyzed the data: YZ, HG.
Wrote the paper: YZ, HG, LL. All authors read and approved the final.
Acknowledgments
We thank the National Health and Family Planning Commission of China for
coordinating data collection and analysis. This study was funded by
Important National Science and Technology Project-Research of Clinical
Treatment for Emerging severe acute respiratory infectious disease
(2014ZX10004006).
Received: 16 July 2015 Accepted: 25 January 2016
References
1. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, et al. Association between adverse
clinical outcome in human disease caused by novel influenza A H7N9 virus
and sustained viral shedding and emergence of antiviral resistance. Lancet
(London, England). 2013;381(9885):2273–9.
2. Galabov AS, Simeonova L, Gegova G. Rimantadine and oseltamivir
demonstrate synergistic combination effect in an experimental infection
with type A (H3N2) influenza virus in mice. Antivir Chem Chemother.
2006;17(5):251–8.
3. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA.
Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1
influenza virus infection in mice. Antimicrob Agents Chemother. 2008;
52(11):3889–97.
4. Ilyushina NA, Hoffmann E, Salomon R, Webster RG, Govorkova EA.
Amantadine-oseltamivir combination therapy for H5N1 influenza virus
infection in mice. Antivir Ther. 2007;12(3):363–70.
5. Smee DF, Bailey KW, Morrison AC, Sidwell RW. Combination treatment of
influenza A virus infections in cell culture and in mice with the
cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin.
Chemotherapy. 2002;48(2):88–93.
6. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double
combinations of amantadine, oseltamivir, and ribavirin on influenza A
(H5N1) virus infections in cell culture and in mice. Antimicrob Agents
Chemother. 2009;53(5):2120–8.
7. Marjuki H, Mishin VP, Chesnokov AP, Jones J, De La Cruz JA, Sleeman K, et al.
Characterization of drug-resistant influenza A(H7N9) variants isolated from an
oseltamivir-treated patient in Taiwan. J Infect Dis. 2015;211(2):249–57.
8. Smee DF, Hurst BL, Wong MH, Tarbet EB, Babu YS, Klumpp K, et al.
Combinations of oseltamivir and peramivir for the treatment of
influenza A (H1N1) virus infections in cell culture and in mice. Antivir
Res. 2010;88(1):38–44.
9. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patick AK, Faix DJ, et al. Triple
combination of amantadine, ribavirin, and oseltamivir is highly active and
synergistic against drug resistant influenza virus strains in vitro. PLoS One.
2010;5(2):e9332.
10. Pizzorno A, Abed Y, Rheaume C, Boivin G. Oseltamivir-zanamivir
combination therapy is not superior to zanamivir monotherapy in
mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses.
Antivir Res. 2014;105:54–8.
11. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M,
Tibi A, et al. Efficacy of oseltamivir-zanamivir combination compared to
each monotherapy for seasonal influenza: a randomized placebo-controlled
trial. PLoS Med. 2010;7(11):e1000362.
12. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection
with a novel avian-origin influenza A (H7N9) virus. N Engl J Med.
2013;368(20):1888–97.
13. Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of
human infections with avian influenza A(H7N9) virus in China. N Engl
J Med. 2014;370(6):520–32.
14. Yu H, Liao Q, Yuan Y, Zhou L, Xiang N, Huai Y, et al. Effectiveness of
oseltamivir on disease progression and viral RNA shedding in patients with
mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of
medical charts in China. BMJ (Clinical Research Ed). 2010;341:c4779.
15. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG,
et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the
treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl
J Med. 1997;337(13):874–80.
16. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, et al.
Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating
acute influenza: a randomized controlled trial. US Oral Neuraminidase Study
Group. JAMA. 2000;283(8):1016–24.
17. Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp
M, et al. Oseltamivir-zanamivir bitherapy compared to oseltamivir
monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus
infections. Antivir Res. 2012;96(2):130–7.
18. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus
activity of peramivir in mice with single intramuscular injection. Antivir
Res. 2006;69(1):39–45.
19. Adisasmito W, Chan PK, Lee N, Oner AF, Gasimov V, Aghayev F, et al.
Effectiveness of antiviral treatment in human influenza A(H5N1) infections:
analysis of a Global Patient Registry. J Infect Dis. 2010;202(8):1154–60.
Zhang et al. BMC Infectious Diseases  (2016) 16:76 Page 7 of 8
20. Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L. Influenza-associated
pneumonia among hospitalized patients with 2009 pandemic influenza A
(H1N1) virus–United States, 2009. Clin Infect Dis. 2012;54(9):1221–9.
21. Leung YH, To MK, Lam TS, Yau SW, Leung OS, Chuang SK. Epidemiology of
human influenza A(H7N9) infection in Hong Kong. J Microbiol Immunol
Infect. 2015;S1684-1182(15)00772-0.
22. Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases
of influenza A (H7N9) virus infection. N Engl J Med. 2013;368(24):2277–85.
23. Stech J, Xiong X, Scholtissek C, Webster RG. Independence of evolutionary
and mutational rates after transmission of avian influenza viruses to swine.
J Virol. 1999;73(3):1878–84.
24. Petersen E, Keld DB, Ellermann-Eriksen S, Gubbels S, Ilkjaer S, Jensen-Fangel
S, et al. Failure of combination oral oseltamivir and inhaled zanamivir
antiviral treatment in ventilator- and ECMO-treated critically ill patients with
pandemic influenza A (H1N1)v. Scand J Infect Dis. 2011;43(6–7):495–503.
25. Lee N, Hui DS, Zuo Z, Ngai KL, Lui GC, Wo SK, et al. A prospective intervention
study on higher-dose oseltamivir treatment in adults hospitalized with
influenza a and B infections. Clin Infect Dis. 2013;57(11):1511–9.
26. South East Asia Infectious Disease Clinical Research Network. Effect of
double dose oseltamivir on clinical and virological outcomes in children
and adults admitted to hospital with severe influenza: double blind
randomised controlled trial. BMJ (Clinical Research Ed). 2013;346:f3039.
27. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P.
Duration of influenza A virus shedding in hospitalized patients and implications
for infection control. Infect Control Hosp Epidemiol. 2007;28(9):1071–6.
28. Frank AL, Taber LH, Wells CR, Wells JM, Glezen WP, Paredes A. Patterns
of shedding of myxoviruses and paramyxoviruses in children. J Infect
Dis. 1981;144(5):433–41.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Zhang et al. BMC Infectious Diseases  (2016) 16:76 Page 8 of 8
